Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301


We’re excited about the products we have in the pipeline and the impact they will have on patients.

Product Indication Preclinical Phase One Phase Two Phase Three Commercial Rights
Retinal Disease Programs
KIO-301 (Intravitreal) Retinitis Pigmentosa (Mutation Agnostic)
Théa Open Innovation
(global less Asia)
Stargardt Disease
KIO-104 (Intravitreal) Posterior Non-Infectious Uveitis
Kiora Pharmaceuticals
Proliferative Vitreoretinopathy
KIO-301 received Orphan Drug Designation from the FDA – March 2022.
KIO-104 received Orphan Drug Designation (EU) – May 2015.
Loading RSS Feed